O	0	10	Comparison
O	11	13	of
B-intervention	14	25	anastrozole
O	26	32	versus
B-control	33	42	tamoxifen
O	43	45	as
O	46	58	preoperative
O	59	66	therapy
O	67	69	in
O	70	84	postmenopausal
O	85	90	women
O	91	95	with
O	96	103	hormone
O	104	112	receptor
O	112	113	-
O	113	121	positive
O	122	128	breast
O	129	135	cancer
O	135	136	:
O	137	140	the
O	141	144	Pre
O	144	145	-
O	145	154	Operative
O	155	156	"
O	156	164	Arimidex
O	164	165	"
O	166	174	Compared
O	175	177	to
O	178	187	Tamoxifen
O	188	189	(
O	189	195	PROACT
O	195	196	)
O	197	202	trial
O	202	203	.

O	204	207	The
O	208	211	Pre
O	211	212	-
O	212	221	Operative
O	222	223	"
O	223	231	Arimidex
O	231	232	"
O	233	241	Compared
O	242	244	to
O	245	254	Tamoxifen
O	255	256	(
O	256	262	PROACT
O	262	263	)
O	264	269	study
O	270	273	was
O	274	275	a
O	276	286	randomized
O	286	287	,
O	288	299	multicenter
O	300	305	study
O	306	315	comparing
O	316	327	anastrozole
O	328	332	with
O	333	342	tamoxifen
O	343	345	as
O	346	347	a
O	348	360	preoperative
O	361	370	treatment
O	371	373	of
O	374	388	postmenopausal
O	389	394	women
O	395	399	with
O	400	405	large
O	405	406	,
O	407	415	operable
O	416	417	(
O	417	419	T2
O	419	420	/
O	420	421	3
O	421	422	,
O	423	425	N0
O	425	426	-
O	426	427	2
O	427	428	,
O	429	431	M0
O	431	432	)
O	432	433	,
O	434	436	or
O	437	448	potentially
O	449	457	operable
O	458	459	(
O	459	462	T4b
O	462	463	,
O	464	466	N0
O	466	467	-
O	467	468	2
O	468	469	,
O	470	472	M0
O	472	473	)
O	474	480	breast
O	481	487	cancer
O	487	488	.

O	489	492	The
O	493	499	effect
O	500	502	of
O	503	515	preoperative
O	516	525	endocrine
O	526	533	therapy
O	534	536	in
O	537	545	patients
O	546	555	scheduled
O	556	559	for
O	560	570	mastectomy
O	571	573	or
O	574	578	with
O	579	589	inoperable
O	590	596	tumors
O	597	599	at
O	600	608	baseline
O	609	612	was
O	613	617	also
O	618	630	investigated
O	630	631	.

B-eligibility	632	640	Patients
I-eligibility	641	645	with
I-eligibility	646	653	hormone
I-eligibility	654	662	receptor
I-eligibility	662	663	-
I-eligibility	663	671	positive
I-eligibility	672	678	breast
I-eligibility	679	685	cancer
O	686	694	received
O	695	706	anastrozole
O	707	708	(
O	708	709	n
O	710	711	=
B-intervention-participants	712	715	228
O	715	716	)
O	717	719	or
O	720	729	tamoxifen
O	730	731	(
O	731	732	n
O	733	734	=
B-control-participants	735	738	223
O	738	739	)
O	740	744	with
O	745	747	or
O	748	755	without
O	756	768	chemotherapy
O	769	772	for
O	773	775	12
O	776	781	weeks
O	782	788	before
O	789	796	primary
O	797	804	surgery
O	804	805	.

B-outcome	806	815	Objective
I-outcome	816	825	responses
O	826	829	for
O	830	841	anastrozole
O	842	845	and
O	846	855	tamoxifen
O	856	864	occurred
O	865	867	in
B-iv-bin-percent	868	870	39
I-iv-bin-percent	870	871	.
I-iv-bin-percent	871	872	5
I-iv-bin-percent	872	873	%
O	874	877	and
B-cv-bin-percent	878	880	35
I-cv-bin-percent	880	881	.
I-cv-bin-percent	881	882	4
I-cv-bin-percent	882	883	%
O	884	886	of
O	887	895	patients
O	895	896	,
O	897	909	respectively
O	910	911	(
B-outcome	911	921	ultrasound
I-outcome	922	934	measurements
O	934	935	)
O	935	936	,
O	937	940	and
B-iv-bin-percent	941	943	50
I-iv-bin-percent	943	944	.
I-iv-bin-percent	944	945	0
I-iv-bin-percent	945	946	%
O	947	950	and
B-cv-bin-percent	951	953	46
I-cv-bin-percent	953	954	.
I-cv-bin-percent	954	955	2
I-cv-bin-percent	955	956	%
O	957	959	of
O	960	968	patients
O	968	969	,
O	970	982	respectively
O	983	984	(
B-outcome	984	991	caliper
I-outcome	992	1004	measurements
O	1004	1005	)
O	1005	1006	.

O	1007	1009	In
O	1010	1018	hormonal
O	1019	1026	therapy
O	1026	1027	-
O	1027	1031	only
O	1032	1040	patients
O	1041	1042	(
O	1042	1043	n
O	1044	1045	=
O	1046	1049	314
O	1049	1050	)
O	1050	1051	,
B-outcome	1052	1060	feasible
I-outcome	1061	1068	surgery
O	1069	1071	at
O	1072	1080	baseline
O	1081	1089	improved
B-outcome	1090	1095	after
I-outcome	1096	1097	3
I-outcome	1098	1104	months
O	1105	1107	in
B-iv-bin-percent	1108	1110	43
I-iv-bin-percent	1110	1111	.
I-iv-bin-percent	1111	1112	0
I-iv-bin-percent	1112	1113	%
O	1114	1116	of
O	1117	1125	patients
O	1126	1135	receiving
O	1136	1147	anastrozole
O	1148	1151	and
B-cv-bin-percent	1152	1154	30
I-cv-bin-percent	1154	1155	.
I-cv-bin-percent	1155	1156	8
I-cv-bin-percent	1156	1157	%
O	1158	1167	receiving
O	1168	1177	tamoxifen
O	1178	1179	(
O	1179	1180	P
O	1181	1182	=
O	1183	1184	.
O	1184	1186	04
O	1186	1187	)
O	1187	1188	.

O	1189	1191	In
O	1192	1195	the
O	1196	1202	intent
O	1202	1203	-
O	1203	1205	to
O	1205	1206	-
O	1206	1211	treat
O	1212	1222	population
O	1222	1223	,
O	1224	1235	improvement
O	1236	1238	in
B-outcome	1239	1247	feasible
I-outcome	1248	1255	surgery
O	1256	1258	at
O	1259	1267	baseline
O	1268	1270	to
O	1271	1277	actual
O	1278	1285	surgery
B-outcome	1286	1288	at
I-outcome	1289	1290	3
I-outcome	1291	1297	months
O	1298	1301	was
O	1302	1307	found
O	1308	1310	to
O	1311	1313	be
O	1314	1325	numerically
O	1326	1332	higher
O	1333	1335	in
O	1336	1339	the
O	1340	1351	anastrozole
O	1352	1357	group
O	1358	1366	compared
O	1367	1371	with
O	1372	1375	the
O	1376	1385	tamoxifen
O	1386	1391	group
O	1391	1392	,
O	1393	1401	although
O	1402	1406	this
O	1407	1417	difference
O	1418	1421	did
O	1422	1425	not
O	1426	1431	reach
O	1432	1444	significance
O	1444	1445	.

O	1446	1450	Drug
O	1450	1451	-
O	1451	1458	related
B-outcome	1459	1466	adverse
I-outcome	1467	1473	events
O	1474	1478	were
O	1479	1487	reported
O	1488	1490	in
B-iv-bin-percent	1491	1493	20
I-iv-bin-percent	1493	1494	.
I-iv-bin-percent	1494	1495	2
I-iv-bin-percent	1495	1496	%
O	1497	1500	and
B-cv-bin-percent	1501	1503	18
I-cv-bin-percent	1503	1504	.
I-cv-bin-percent	1504	1505	1
I-cv-bin-percent	1505	1506	%
O	1507	1509	of
O	1510	1518	patients
O	1518	1519	,
O	1520	1532	respectively
O	1532	1533	,
O	1534	1536	in
O	1537	1540	the
O	1541	1552	anastrozole
O	1553	1556	and
O	1557	1566	tamoxifen
O	1567	1573	groups
O	1573	1574	.

O	1575	1586	Anastrozole
O	1587	1589	is
O	1590	1592	an
B-outcome	1593	1602	effective
I-outcome	1603	1606	and
I-outcome	1607	1611	well
I-outcome	1611	1612	-
I-outcome	1612	1621	tolerated
O	1622	1634	preoperative
O	1635	1642	therapy
O	1642	1643	,
O	1644	1653	producing
O	1654	1664	clinically
O	1665	1675	beneficial
O	1676	1681	tumor
O	1682	1693	downstaging
O	1694	1697	and
O	1698	1708	reductions
O	1709	1711	in
O	1712	1717	tumor
O	1718	1724	volume
O	1724	1725	.

O	1726	1731	These
O	1732	1739	effects
O	1740	1746	enable
O	1747	1751	more
O	1752	1759	minimal
O	1760	1768	surgical
O	1769	1782	interventions
O	1783	1785	in
O	1786	1794	patients
O	1795	1804	scheduled
O	1805	1808	for
O	1809	1819	mastectomy
O	1819	1820	,
O	1821	1824	and
O	1825	1835	mastectomy
O	1836	1838	in
O	1839	1847	patients
O	1848	1852	with
O	1853	1863	previously
O	1864	1874	inoperable
O	1875	1881	tumors
O	1881	1882	.

O	1883	1894	Anastrozole
O	1895	1902	appears
O	1903	1905	to
O	1906	1908	be
O	1909	1911	at
O	1912	1917	least
O	1918	1920	as
O	1921	1930	effective
O	1931	1933	as
O	1934	1943	tamoxifen
O	1944	1946	in
O	1947	1951	this
O	1952	1959	setting
O	1959	1960	,
O	1961	1964	and
O	1965	1969	more
O	1970	1979	effective
O	1980	1984	than
O	1985	1994	tamoxifen
O	1995	1997	in
O	1998	2005	certain
O	2006	2016	clinically
O	2017	2025	relevant
O	2026	2035	subgroups
O	2035	2036	.

O	2037	2043	Cancer
O	2044	2048	2006
O	2048	2049	.

O	2050	2051	(
O	2051	2052	c
O	2052	2053	)
O	2054	2058	2006
O	2059	2067	American
O	2068	2074	Cancer
O	2075	2082	Society
O	2082	2083	.
